TABLE 1
Profile of intravenously administered NK 1 RAs
Agent Excipients (inactive ingredients)
Aprepitant IV 40 Egg lecithin, ethanol, sodium oleate,
soybean oil, sucrose, and water for
injection
Fosprepitant IV 30 Disodium edetate, Polysorbate
80, Lactose anhydrous, sodium
hydroxide (for pH adjustment) and/
or hydrochloric acid diluted (for pH
adjustment)
NEPA IV
(fosnetupitant; palonosetron) 46 Disodium edetate, mannitol, sodium
hydroxide and/or hydrochloric acid
(for pH adjustment)
Rolapitant 52,53 Dibasic sodium phosphate,
anhydrous, medium chain
triglycerides, polyoxyl 15
hydroxystearate, sodium chloride,
soybean oil, water for injection and
may contain hydrochloric acid and/
or sodium hydroxide to adjust pH to
7.0 to 8.0.
aprepitant has been licensed in the
US based on data demonstrating
equivalence of aprepitant
injectable emulsion to IV
fosaprepitant. 36,40,41
In clinical trials, the
aprepitant injectable emulsion
(HTX-019), was shown to be
generally well tolerated and
58 | 2019 | hospitalpharmacyeurope.com
bioequivalent to commercially
available fosaprepitant without
the risk of polysorbate 80
surfactant–associated systemic
hypersensitivity and infusion-site
adverse events. 36 Data showed
that patients receiving aprepitant
injectable emulsion had fewer
treatment-emergent adverse